A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
- PMID: 3902203
- DOI: 10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e
A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
Abstract
A randomized evaluation of the effectiveness and toxicity of the combination of doxorubicin and cisplatin and of doxorubicin alone in patients with advanced thyroid carcinoma was carried out. Ninety-two patients were entered and 84 were evaluable. They were stratified according to histological classification, Eastern Cooperative Oncology Group (ECOG) performance status, and metastatic sites. Forty-one patients received doxorubicin as a single agent and seven had partial response (17%). Forty-three patients received the combination, and there were five complete and six partial responses (combined response rate of 26%). This difference for overall response rate is not significant (P greater than 0.1). However, five complete responses were seen in the combination-treatment group, whereas none were observed in the single-agent treatment group; a significant difference was obtained (P = 0.03). Four of these five complete responders survived for more than 2 years, and two patients remained in a complete response after the discontinuation of therapy and are still alive. None of the partial responses exceeded 2 years in duration. The life-threatening toxicities from chemotherapy occurred in five patients treated with the combination of drugs and two treated with doxorubicin alone. However, none of the toxicities were fatal. The study has shown clearly that the quality of response achieved by the combination of drugs is far superior to that achieved by single-agent chemotherapy.
Similar articles
-
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.Cancer. 1996 Feb 15;77(4):733-42. Cancer. 1996. PMID: 8616766 Clinical Trial.
-
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma.Cancer. 1985 Dec 1;56(11):2580-6. doi: 10.1002/1097-0142(19851201)56:11<2580::aid-cncr2820561108>3.0.co;2-w. Cancer. 1985. PMID: 4052935 Clinical Trial.
-
Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience.J BUON. 2009 Jan-Mar;14(1):41-4. J BUON. 2009. PMID: 19373945
-
Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.Gynecol Oncol. 1994 Dec;55(3 Pt 2):S97-107. doi: 10.1006/gyno.1994.1347. Gynecol Oncol. 1994. PMID: 7835816 Review.
-
Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience.Cancer. 1988 Aug 15;62(4):683-5. doi: 10.1002/1097-0142(19880815)62:4<683::aid-cncr2820620406>3.0.co;2-j. Cancer. 1988. PMID: 3293760 Review.
Cited by
-
The value of multimodal treatment in anaplastic thyroid cancer patients with distant metastasis.BMC Surg. 2024 Mar 4;24(1):79. doi: 10.1186/s12893-024-02375-6. BMC Surg. 2024. PMID: 38438944 Free PMC article.
-
Development and validation of a nomogram for predicting the early death of anaplastic thyroid cancer: a SEER population-based study.J Cancer Res Clin Oncol. 2023 Nov;149(17):16001-16013. doi: 10.1007/s00432-023-05302-z. Epub 2023 Sep 9. J Cancer Res Clin Oncol. 2023. PMID: 37689588
-
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer.Thyroid Res. 2023 Mar 1;16(1):5. doi: 10.1186/s13044-023-00147-7. Thyroid Res. 2023. PMID: 36855200 Free PMC article.
-
Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.J Cancer Res Clin Oncol. 2023 Jul;149(7):3527-3547. doi: 10.1007/s00432-022-04223-7. Epub 2022 Aug 12. J Cancer Res Clin Oncol. 2023. PMID: 35960373 Free PMC article.
-
Revisiting Combination Chemotherapy as a Single Modality Palliative Therapy for Advanced Anaplastic Thyroid Carcinoma-a Single Institution Experience.Indian J Surg Oncol. 2022 Mar;13(1):208-215. doi: 10.1007/s13193-021-01401-w. Epub 2021 Aug 2. Indian J Surg Oncol. 2022. PMID: 35462645 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical